{"gene":"ZHX2","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2004,"finding":"ZHX2 (Afr1) functions as a transcriptional repressor responsible for postnatal silencing of alpha-fetoprotein (AFP) and H19 in the liver. Liver-specific overexpression of a Zhx2 transgene in BALB/cJ mice (which carry a retroviral insertion disrupting Zhx2) restored wild-type H19 repression, directly demonstrating that Zhx2 is the gene responsible for hereditary persistence of AFP and H19.","method":"Transgenic complementation in BALB/cJ mice with liver-specific Zhx2 overexpression; positional cloning/mapping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic rescue experiment with clear functional readout, replicated in subsequent studies from multiple labs","pmids":["15626755"],"is_preprint":false},{"year":2003,"finding":"ZHX2 forms a heterodimer with ZHX3 via a region containing homeodomain 1 (HD1), demonstrated by in vitro and in vivo protein-protein interaction assays. ZHX family members (ZHX1, ZHX2, ZHX3) act as ubiquitous transcriptional repressors and can form both homodimers and heterodimers.","method":"In vitro and in vivo protein-protein interaction assays (co-immunoprecipitation/pull-down); cDNA cloning and expression analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct protein-protein interaction assays in one study, consistent with family-level characterization","pmids":["14659886"],"is_preprint":false},{"year":2009,"finding":"ZHX2 is expressed specifically in neural progenitor cells during cortical neurogenesis and binds to the cytoplasmic domain of ephrin-B1. ZHX2 acts as a transcriptional repressor, and its repressor activity is enhanced by co-expression with the ephrin-B1 intracellular domain. Blocking ZHX2 function causes neuronal differentiation, while overexpression of ZHX2 with ephrin-B1 intracellular domain disrupts normal differentiation of cortical neural progenitor cells.","method":"Co-immunoprecipitation (ZHX2 binding ephrin-B1); loss-of-function and gain-of-function in cultured neural progenitor cells and embryonic cortex; transcriptional repressor assay","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct binding shown by Co-IP, loss- and gain-of-function with defined phenotype, single lab","pmids":["19515908"],"is_preprint":false},{"year":2009,"finding":"Zhx2 functions as a novel developmental regulator of hepatic lipoprotein metabolism. Reduced Zhx2 expression in BALB/cJ mice causes failure to suppress lipoprotein lipase (LPL) expression in adult liver, a gene normally silenced postnatally; Zhx2 transgene in BALB/cJ mice normalized hepatic LPL expression. QTL mapping and transgenic complementation identified Zhx2 as the gene underlying a chromosome 15 QTL for HDL cholesterol and triglyceride levels.","method":"QTL mapping with congenic strains; transgenic complementation; microarray analysis of hepatic gene expression","journal":"Circulation. Cardiovascular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — QTL fine-mapping combined with transgenic rescue and gene expression analysis, replicates findings from the Spear lab","pmids":["20160197"],"is_preprint":false},{"year":2018,"finding":"ZHX2 is a substrate of the VHL E3 ubiquitin ligase complex: VHL regulates ZHX2 protein stability via hydroxylation-dependent ubiquitination. Loss of VHL in ccRCC leads to increased ZHX2 abundance and nuclear localization. ZHX2 promotes NF-κB activation in ccRCC, as demonstrated by integrated ChIP-seq and microarray analysis, and ZHX2 depletion inhibits VHL-deficient ccRCC cell growth in vitro and in vivo.","method":"Genome-wide in vitro expression/binding screen for VHL substrates; protein stability assays; ChIP-seq; microarray; in vitro and in vivo tumor growth assays (knockdown)","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (binding screen, stability assay, ChIP-seq, in vivo), highly cited, independently followed up","pmids":["30026228"],"is_preprint":false},{"year":2015,"finding":"ZHX2 represses MDR1 (multidrug resistance 1) transcription by interacting with NF-YA and reducing NF-Y binding to the MDR1 promoter. Co-IP and ChIP assays showed ZHX2 physically interacts with NF-YA; luciferase reporter assays showed ZHX2-mediated repression of MDR1 promoter is abolished by NF-YA knockdown or mutation of the NF-Y binding site. Increased ZHX2 enhances chemosensitivity in HCC cells in vitro and in vivo.","method":"Co-immunoprecipitation; ChIP assay; luciferase reporter assay; in vitro drug sensitivity assays; in vivo xenograft","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal Co-IP and ChIP with functional reporter validation, single lab","pmids":["25473899"],"is_preprint":false},{"year":2014,"finding":"ZHX2 directly binds the core promoter of GPC3 (glypican 3) and suppresses its transcription. Nuclear translocation of ZHX2 is required for this repression. Loss of nuclear ZHX2 in HCC is responsible for GPC3 reactivation.","method":"Dual luciferase reporter assay; ChIP assay; ZHX2 overexpression/knockdown in HCC cell lines; immunohistochemistry; nuclear translocation experiments","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and luciferase reporter with nuclear localization requirement established, single lab","pmids":["25195714"],"is_preprint":false},{"year":2018,"finding":"ZHX2 restricts HBV replication by binding to HBV cccDNA and transcriptionally inhibiting HBV promoter activities. ZHX2 also suppresses expression of histone regulator genes including p300/CBP that bind cccDNA, leading to epigenetic repression of cccDNA transcription.","method":"Dual luciferase assay; cccDNA ChIP assay; ZHX2 overexpression/knockdown in vitro and in mouse liver models; immunohistochemistry; measurement of HBV antigens and DNA","journal":"Antiviral research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — cccDNA ChIP directly demonstrates binding, multiple readouts, single lab","pmids":["29580980"],"is_preprint":false},{"year":2018,"finding":"HBV X protein (HBx) inhibits ZHX2 expression via upregulation of miR-155, which targets the ZHX2 3'UTR. miR-155 overexpression reduced ZHX2 levels through its seed sites in the ZHX2 3'UTR, and blocking miR-155 increased ZHX2 levels. This pathway links HBV oncogenic properties to ZHX2 suppression.","method":"miR-155 overexpression/blockade experiments; 3'UTR reporter assay; in vitro and in vivo HBV/HBx overexpression models; qPCR and Western blot","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — 3'UTR reporter and miRNA blockade experiments across in vitro and in vivo models, single lab","pmids":["29752719"],"is_preprint":false},{"year":2019,"finding":"ZHX2 inhibits lipid uptake in hepatocytes by transcriptionally suppressing lipoprotein lipase (LPL). ZHX2 overexpression decreased LPL transcription, inhibited exogenous lipid uptake, and reduced HCC cell proliferation; LPL overexpression reversed ZHX2-mediated inhibition. ZHX2 and LPL show inverse correlation in HCC patient samples.","method":"ZHX2 overexpression/knockdown in HCC cell lines; in vitro and in vivo lipid uptake assays; LPL rescue overexpression; xenograft tumor growth; IHC in patient cohort","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — epistasis rescue experiment (LPL reversal), in vivo xenograft, IHC correlation, single lab","pmids":["31740790"],"is_preprint":false},{"year":2020,"finding":"ZHX2 enhances macrophage glycolysis and promotes sepsis pathogenesis by directly binding to the Pfkfb3 promoter and enhancing Pfkfb3 transcription. Myeloid-specific Zhx2 deletion reduced Pfkfb3 expression and macrophage glycolytic rate; Pfkfb3 overexpression rescued the glycolysis defect caused by Zhx2 deficiency. This was demonstrated by RNA-seq and ChIP assays.","method":"Myeloid-specific conditional knockout mice; RNA sequencing; ChIP assay (Zhx2 binding Pfkfb3 promoter); Pfkfb3 rescue overexpression; extracellular acidification rate and lactate measurement; cecal ligation and puncture (CLP) and LPS sepsis models","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with genetic rescue, direct ChIP evidence of promoter binding, in vivo and in vitro mechanistic chain, single lab but multiple orthogonal approaches","pmids":["32179636"],"is_preprint":false},{"year":2020,"finding":"ZHX2 suppresses HCC progression by inhibiting de novo lipogenesis via transcriptional upregulation of miR-24-3p, which targets and promotes degradation of SREBP1c. ZHX2 overexpression reduced FASN, ACL, ACC1, and SCD1; ZHX2-mediated effects were reversed by SREBP1c overexpression; liver-specific Zhx2 KO mice showed increased spontaneous tumor formation reversed by SREBP1c inhibitor fatostatin.","method":"ZHX2 overexpression/knockdown in HCC cells; miR-24-3p rescue/inhibition; SREBP1c overexpression rescue; Zhx2 liver-specific knockout mice; fatostatin treatment; qPCR and Western blot","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vivo KO model with genetic epistasis (fatostatin rescue), miRNA mechanism validated, single lab","pmids":["32770671"],"is_preprint":false},{"year":2020,"finding":"ZHX2 suppresses liver cancer stem cell (CSC) traits by transcriptionally repressing KDM2A (a histone H3K36 demethylase). ZHX2 inhibits KDM2A-mediated demethylation of H3K36 at promoters of stemness transcription factors NANOG, SOX4, and OCT4, thereby restricting CSC self-renewal, tumor initiation, and sorafenib resistance. This was demonstrated by microarray, luciferase reporter, ChIP, and ChIP-on-chip analyses.","method":"ChIP; ChIP-on-chip; luciferase reporter assay; microarray; ZHX2 overexpression/knockdown in sorted CSC populations; in vivo tumor initiation assays","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP-on-chip and ChIP directly link ZHX2 to KDM2A promoter, multiple orthogonal methods, single lab","pmids":["32114388"],"is_preprint":false},{"year":2020,"finding":"ZHX2 overexpression drives ccRCC cell growth and migration through transcriptional activation of MEK/ERK1/2 signaling and its downstream targets, and also increases VEGF secretion. ZHX2 overexpression induces sunitinib resistance through activating autophagy.","method":"Lentiviral overexpression/knockdown in VHL-deficient (786-O) and VHL-normal (CAKI-1) cell lines; in vitro and in vivo growth/migration assays; Western blot for MEK/ERK pathway; autophagic flux measurement; drug sensitivity assay with chloroquine rescue","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, primarily overexpression/knockdown without direct transcriptional binding evidence for MEK/ERK pathway activation","pmids":["32382017"],"is_preprint":false},{"year":2021,"finding":"ZHX2 physically interacts with HIF family members (HIF1α) and positively regulates HIF1α transcriptional activity in triple-negative breast cancer (TNBC). ZHX2 and HIF1α co-occupy transcriptionally active promoters marked by H3K4me3 and H3K27ac, as shown by integrated ChIP-seq and gene expression profiling. Residues R491, R581, and R674 on ZHX2 are important for its transcriptional activity and oncogenic phenotype in TNBC.","method":"Co-immunoprecipitation (ZHX2-HIF1α); ChIP-seq; gene expression profiling; ZHX2 point mutant analysis; ZHX2 knockdown with in vitro and in vivo tumor growth assays; rescue by overexpression of target genes","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP-seq, functional mutagenesis of ZHX2 residues, in vitro and in vivo models, multiple orthogonal methods in single rigorous study","pmids":["34779768"],"is_preprint":false},{"year":2021,"finding":"ZHX2 transcriptionally represses Zeb2 (a key transcription factor for NK cell terminal maturation) in NK cells, thereby restricting NK cell maturation and survival. Conditional deletion of Zhx2 in NK cells resulted in accumulation of mature NK cells and enhanced NK cell response to IL-15, with Zeb2 identified as a direct downstream target.","method":"NK cell-specific conditional Zhx2 knockout mice; transcriptomic analysis; in vivo tumor models with Zhx2-deficient NK cell transfer; assessment of NK cell maturation markers","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with transcriptomic target identification, in vivo functional assay, single lab","pmids":["34279541"],"is_preprint":false},{"year":2022,"finding":"USP13 is a deubiquitinase (DUB) that binds ZHX2 and promotes ZHX2 deubiquitination and protein stability in an enzymatically dependent manner. USP13 depletion leads to ZHX2 downregulation in ccRCC and decreased tumor cell proliferation in vitro and in vivo; the effect of USP13 on ccRCC growth is partially mediated through ZHX2.","method":"DUB cDNA library binding screen; co-immunoprecipitation (USP13-ZHX2); ubiquitination assay; enzymatic mutant USP13 analysis; 2D colony formation and 3D anchorage-independent growth assays; in vivo tumor growth","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — DUB screen followed by Co-IP, ubiquitination assay, enzymatic mutant validation, in vitro and in vivo functional assays, rigorous multi-method study","pmids":["36037364"],"is_preprint":false},{"year":2022,"finding":"ZHX2 is a substrate for N-terminal methylation (Nα-methylation) by the methyltransferase NRMT1. NRMT1 can methylate ZHX2 in vitro, and a methylation-deficient ZHX2 mutant shows reduced transcription factor activity and reduced promoter occupancy. Loss of NRMT1 in mice causes dysregulation of ZHX2 targets (CYP and MUP families) in liver, linking NRMT1-mediated Nα-methylation to ZHX2 function.","method":"In vitro methylation assay (NRMT1 + ZHX2); methylation-deficient ZHX2 mutant analysis; RNA-seq of NRMT1 knockout mouse livers; promoter occupancy assay; Western blot and qPCR","journal":"Transcription","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro methylation assay and methylation-deficient mutant with functional readout, single lab","pmids":["35613330"],"is_preprint":false},{"year":2023,"finding":"ZHX2 is a negative regulator of mitochondrial oxidative phosphorylation (OXPHOS) during acute liver injury. ZHX2 both transcriptionally inhibits expression of mitochondrial electron transport chain genes and decreases PGC-1α protein stability, leading to reduced mitochondrial mass and OXPHOS. Loss of Zhx2 promotes liver recovery after partial hepatectomy or CCl4 injury by increasing mitochondrial OXPHOS; inhibition of PGC-1α or ETC abolishes these protective effects.","method":"Conditional Zhx2 knockout mice; partial hepatectomy and CCl4 liver injury models; measurement of mitochondrial mass and OXPHOS; transcriptional analysis of ETC genes; PGC-1α stability assay; shRNA delivery in vivo","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo with epistasis rescue (PGC-1α/ETC inhibition abolishes effect), two injury models, multiple mechanistic arms, single lab but multiple orthogonal approaches","pmids":["37980429"],"is_preprint":false},{"year":2023,"finding":"ZHX2 associates with NF-κB p65 and binds to the Irf1 promoter to transcriptionally activate Irf1 in macrophages, thereby controlling macrophage polarization. Myeloid-specific Zhx2 deletion suppresses LPS-induced proinflammatory polarization but promotes IL-4- and tumor microenvironment-induced pro-tumoral macrophage phenotype. Lactate from the tumor microenvironment decreases Zhx2 expression, leading to a switch toward pro-tumor TAM phenotype.","method":"Myeloid-specific Zhx2 conditional KO mice; co-immunoprecipitation (ZHX2-p65); ChIP/reporter assay (Irf1 promoter); murine liver tumor models; macrophage polarization assays; Western blot","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP for mechanism, conditional KO with functional phenotype, single lab","pmids":["37582865"],"is_preprint":false},{"year":2023,"finding":"ZHX2 transcriptionally activates Pax6 by binding to the Pax6 promoter region (positions -1740 to -1563, -862 to -559, and -251 to +75). β-cell-specific Zhx2 knockout mice showed decreased β-cell proliferation, reduced β-cell mass, and impaired glucose homeostasis, demonstrating a role for Zhx2 in maintaining β-cell mass and function via Pax6 regulation.","method":"β-cell-specific Zhx2 knockout mice; ChIP assay (Zhx2 binding Pax6 promoter); luciferase reporter assay; glucose tolerance tests; insulin secretion measurements","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and reporter assay with tissue-specific KO mouse model, single lab","pmids":["37275527"],"is_preprint":false},{"year":2023,"finding":"ZHX2 transcriptionally inhibits GADD34 expression by binding to its promoter, thereby enhancing endoplasmic reticulum stress-mediated anticancer effects of I-125 radiation in HCC. This was part of a circSEC11A/miR-3529-3p/ZHX2/GADD34 axis.","method":"Dual-luciferase reporter assay; RNA pull-down; RNA immunoprecipitation; FISH; in vitro and in vivo anticancer effect assays (CCK-8, flow cytometry, TUNEL, EdU, transwell)","journal":"Cell death discovery","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mechanistic assignment of ZHX2 binding GADD34 promoter supported by reporter assay, but single lab, limited direct ChIP evidence described","pmids":["37563132"],"is_preprint":false},{"year":2023,"finding":"ZHX2 directly binds the CDH1 promoter and represses E-cadherin (CDH1) expression in TNBC cells. Loss of ZHX2 reactivates CDH1, promoting a hybrid mesenchymal-to-epithelial (MET) state and inhibiting cancer cell migration and metastasis. E-cadherin restoration reverses the effects of ZHX2 loss.","method":"ChIP assay (ZHX2 binding CDH1 promoter); ZHX2 knockdown/overexpression; CDH1 rescue overexpression; cell migration assays; in vivo lung metastasis models; organoid culture","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP evidence with functional rescue experiment, in vivo metastasis model, single lab","pmids":["37460540"],"is_preprint":false},{"year":2023,"finding":"ZHX2 positively regulates Elovl3 expression in the liver by directly activating its transcription. Zhx2 loss-of-function in mice reduces Elovl3 levels; Elovl3 expression is repressed during liver regeneration correlating with reduced very long chain fatty acids. Forced Elovl3 expression in human hepatoma cells reduces cell growth and blocks cell cycle progression in S-phase.","method":"Mouse models of Zhx2 loss-of-function; liver regeneration models (partial hepatectomy, CCl4); cell growth assays; cell cycle synchronization; mRNA and protein analysis; VLCFA measurements","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mouse models and cell-based rescue experiment, direct ZHX2-Elovl3 regulatory axis defined, single lab","pmids":["37847682"],"is_preprint":false},{"year":2025,"finding":"ZHX2 undergoes liquid-liquid phase separation (LLPS) in response to hypoxia via a proline-rich intrinsically disordered region (IDR), which enhances chromatin occupancy. Hypoxia induces phosphorylation of ZHX2 at S625 and S628, incorporating CTCF into ZHX2 condensates and altering chromatin looping to activate metastatic gene transcription. This phase separation drives cancer metastasis in breast cancer cells and is distinct from HIF-dependent hypoxia responses.","method":"Phase separation/condensate formation assays; phosphorylation site identification and mutagenesis (S625, S628); CTCF co-immunoprecipitation in condensates; ChIP for chromatin looping; in vivo metastasis models; IDR deletion mutants","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — phase separation reconstitution with mutagenesis of critical phosphosites, CTCF Co-IP in condensates, chromatin looping ChIP, in vivo validation, multiple orthogonal methods","pmids":["40185097"],"is_preprint":false},{"year":2025,"finding":"YAP (Hippo pathway effector) inhibits ZHX2 expression and competes with ZHX2 for binding to the NF-κB subunit p65. Elevated nuclear YAP blocks the cooperative interaction between ZHX2 and p65, leading to diminished NF-κB target gene expression and suppressed ccRCC cell growth. ZHX2 overexpression or p65 overexpression rescues the anti-proliferative effects of Hippo kinase inhibition.","method":"ZHX2 and p65 co-immunoprecipitation; YAP knockdown/overexpression; pharmacological Hippo kinase inhibition; ZHX2 and p65 overexpression rescue assays; NF-κB target gene expression analysis; ccRCC cell growth assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP showing competitive binding, genetic rescue experiments, single lab","pmids":["40120683"],"is_preprint":false},{"year":2025,"finding":"ZHX2 undergoes LLPS and binds to the SLC3A2 promoter through phase separation, activating SLC3A2 transcription to inhibit ferroptosis in DLBCL cells. ZHX2-siRNA lipid nanoparticles targeting this mechanism suppressed DLBCL tumor growth in vivo.","method":"LLPS assays; ChIP assay (ZHX2 binding SLC3A2 promoter); ZHX2 knockdown/overexpression; ferroptosis assays; in vivo tumor growth with siRNA-LNP","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — LLPS assay with ChIP promoter binding and in vivo functional validation, single lab","pmids":["40730912"],"is_preprint":false},{"year":2025,"finding":"METTL3-mediated m6A methylation of ZHX2 mRNA is recognized by the m6A reader IGF2BP1, which stabilizes ZHX2 mRNA. This m6A modification promotes ZHX2 expression and renal cell carcinoma progression. METTL3 silencing reduces ZHX2, and ZHX2 overexpression reverses the inhibitory effects of METTL3 depletion on RCC tumor growth.","method":"m6A RNA immunoprecipitation assay; RNA immunoprecipitation (IGF2BP1-ZHX2 mRNA); mRNA stability assay (Actinomycin D); METTL3 knockdown; ZHX2 overexpression rescue; xenograft mouse model","journal":"Kidney & blood pressure research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct m6A-RIP and RIP assays with stability measurement and in vivo rescue, single lab","pmids":["39159608"],"is_preprint":false},{"year":2025,"finding":"ZHX2 transcriptionally inhibits YTHDF2 by binding to its promoter region, and in turn YTHDF2 recognizes m6A-modified ZHX2 mRNA to promote its degradation, forming a feedback regulatory loop. ZHX2 overexpression protects against diabetes-induced hepatic ferroptosis by suppressing YTHDF2, which otherwise promotes GPX4 and SLC7A11 degradation.","method":"Luciferase reporter assay; ChIP assay (ZHX2 at YTHDF2 promoter); RNA immunoprecipitation (YTHDF2 binding ZHX2 mRNA); ZHX2 knockdown/overexpression; in vivo HFD/STZ diabetes mouse model; ferroptosis assays","journal":"Nutrition & diabetes","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP, luciferase reporter and RIP for two regulatory directions, in vivo model, single lab","pmids":["39987125"],"is_preprint":false},{"year":2019,"finding":"ZHX2 and ZHX3 form heterodimeric complexes in podocytes, with ZHX2-ZHX1 localized predominantly at the podocyte cell body membrane and ZHX2-ZHX3 at the slit diaphragm. ZHX2 interacts with aminopeptidase A (ENPEP) at the cell body membrane and with ephrin-B1 (EFNB1) at the slit diaphragm, as shown by co-immunoprecipitation. ZHX2 imbalance is a critical factor in glomerular diseases, with ZHX2 sequestering ZHX1 peripherally to regulate its nuclear access.","method":"Co-immunoprecipitation (ZHX2 with aminopeptidase A and ephrin-B1); subcellular fractionation/localization; Zhx2 knockout mice; podocyte-specific Zhx2 overexpressing transgenic rats; glomerular disease models; immunofluorescence","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for protein interactions, in vivo transgenic models with functional phenotype, localization experiments, single lab","pmids":["32059999"],"is_preprint":false},{"year":2020,"finding":"ZHX2 mediates proteasome inhibitor (bortezomib) resistance in multiple myeloma cells by directly binding NF-κB and promoting nuclear translocation of NF-κB. ZHX2 knockdown reduced nuclear NF-κB, decreased NF-κB target gene expression, and enhanced bortezomib sensitivity in myeloma cell lines.","method":"Co-immunoprecipitation (ZHX2-NF-κB); Western blot and immunofluorescence for NF-κB nuclear localization; ZHX2 knockdown; flow cytometry for apoptosis; qRT-PCR for NF-κB target genes","journal":"Cancer medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP for ZHX2-NF-κB interaction, single lab, limited mechanistic depth","pmids":["32780537"],"is_preprint":false},{"year":2022,"finding":"ZHX2 transcriptionally represses S100A14 by binding to its promoter, inhibiting thyroid cancer cell migration and metastasis. S100A14 knockdown reverses ZHX2 depletion-induced enhanced metastasis.","method":"ChIP assay (ZHX2 at S100A14 promoter); ZHX2 knockdown/overexpression; S100A14 knockdown rescue; cell migration assays; in vivo lung metastasis model","journal":"Cancer cell international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and rescue experiment supporting the mechanism, single lab","pmids":["35151335"],"is_preprint":false},{"year":2026,"finding":"ZHX2 transcriptionally represses CRABP1 by binding to its promoter, which modulates retinoid metabolism and enhances retinoic acid (RA) sensitivity in neuroblastoma cells. ZHX2 overexpression inhibited NB malignancy and augmented RA-induced neuronal differentiation in vitro and reduced tumor growth in vivo.","method":"CHIP-qPCR (ZHX2 at CRABP1 promoter); ZHX2 knockdown/overexpression; RNA-seq; cell proliferation, migration, apoptosis assays; in vivo xenograft; differentiation marker analysis","journal":"Biomedicine & pharmacotherapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP-qPCR with functional assays, single lab, published 2026 with limited independent validation","pmids":["42070457"],"is_preprint":false},{"year":2019,"finding":"ZHX2 knockdown in dorsal root ganglion (DRG) neurons reverses CCI (chronic constriction injury)-induced downregulation of μ-opioid receptor expression and alleviates mechanical allodynia in mice. In primary DRG neurons, ZHX2 knockdown upregulated μ-opioid receptor mRNA and protein, indicating ZHX2 represses μ-opioid receptor expression in DRG neurons.","method":"In vivo siRNA microinjection into DRG; RT-qPCR and Western blot for μ-opioid receptor; behavioral testing (paw withdrawal frequency); primary DRG neuron culture with ZHX2 siRNA transfection","journal":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, siRNA knockdown without direct promoter binding evidence, limited mechanistic depth","pmids":["31511211"],"is_preprint":false},{"year":2025,"finding":"ZHX2 transcriptionally inhibits FABP4 by binding to its promoter region, thereby blocking the AGEs/RAGE/NLRP3 pathway and inhibiting podocyte pyroptosis and inflammation in diabetic nephropathy.","method":"ChIP assay (ZHX2 at FABP4 promoter); luciferase reporter assay; ZHX2 overexpression/knockdown; in vitro high-glucose podocyte model; in vivo diabetic nephropathy mouse model; exosome delivery of ZHX2","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and reporter assay supporting FABP4 as direct target, single lab, published 2026 with no independent replication","pmids":["41603587"],"is_preprint":false}],"current_model":"ZHX2 is a multi-context transcription factor that contains zinc-finger and homeodomain motifs, forms homodimers and heterodimers (with ZHX1 and ZHX3), and functions primarily as a transcriptional repressor in the liver (silencing AFP, H19, GPC3, LPL, SREBP1c, MDR1, Pfkfb3 [in macrophages], and mitochondrial ETC genes) but acts as a co-activator in ccRCC and TNBC by binding NF-κB p65 and HIF1α, respectively; its protein stability is regulated by VHL-mediated hydroxylation-dependent ubiquitination and by USP13-mediated deubiquitination, its activity is modulated by NRMT1-catalyzed N-terminal methylation that promotes promoter occupancy, and under hypoxia it undergoes phase separation via a proline-rich IDR with phosphorylation at S625/S628 recruiting CTCF to alter chromatin looping and drive oncogenic metastatic gene transcription."},"narrative":{"mechanistic_narrative":"ZHX2 is a zinc-finger/homeodomain transcription factor that acts predominantly as a sequence-specific repressor of a developmentally silenced gene program in the liver while functioning as a context-dependent co-activator in cancer [PMID:15626755, PMID:30026228]. It was originally identified as the gene responsible for hereditary persistence of alpha-fetoprotein and H19, with liver-specific transgenic complementation restoring postnatal silencing of these loci [PMID:15626755], and it likewise enforces postnatal repression of lipoprotein lipase to control hepatic lipoprotein metabolism [PMID:20160197]. As a repressor it directly binds target promoters (GPC3, MDR1 via NF-YA, mitochondrial ETC genes) and additionally tunes lipid metabolism by driving miR-24-3p-mediated SREBP1c degradation and by destabilizing PGC-1α, thereby restraining de novo lipogenesis and mitochondrial OXPHOS [PMID:25473899, PMID:25195714, PMID:32770671, PMID:37980429]. In clear-cell renal carcinoma ZHX2 switches to an oncogenic co-activator: VHL normally targets it for hydroxylation-dependent ubiquitination, so VHL loss stabilizes and nuclearizes ZHX2, which then associates with NF-κB p65 to activate NF-κB target genes [PMID:30026228]. ZHX2 protein abundance is opposed by USP13-mediated deubiquitination [PMID:36037364], its promoter occupancy depends on NRMT1-catalyzed N-terminal methylation [PMID:35613330], and YAP both suppresses its expression and competes for p65 binding [PMID:40120683]. Under hypoxia ZHX2 undergoes liquid-liquid phase separation through a proline-rich intrinsically disordered region, and phosphorylation at S625/S628 recruits CTCF into condensates to remodel chromatin looping and drive metastatic transcription [PMID:40185097]. Beyond transcription, ZHX2 forms homo- and heterodimers with ZHX1 and ZHX3 [PMID:14659886], and in immune and metabolic settings controls macrophage glycolysis and polarization (Pfkfb3, Irf1/p65), NK cell maturation (Zeb2), and β-cell mass (Pax6) [PMID:32179636, PMID:37582865, PMID:34279541, PMID:37275527].","teleology":[{"year":2003,"claim":"Established that ZHX2 is a member of a family of dimerizing transcriptional repressors, defining its structural basis for action before its physiological targets were known.","evidence":"cDNA cloning with in vitro and in vivo protein-protein interaction assays showing ZHX2-ZHX3 heterodimerization via HD1","pmids":["14659886"],"confidence":"Medium","gaps":["No target genes or promoter specificity defined","Functional consequence of heterodimerization on repression not tested"]},{"year":2004,"claim":"Identified ZHX2 as the causal gene for hereditary persistence of AFP/H19, answering what enforces postnatal silencing of fetal liver genes.","evidence":"Positional cloning and liver-specific Zhx2 transgenic complementation in BALB/cJ mice","pmids":["15626755"],"confidence":"High","gaps":["Direct promoter binding to AFP/H19 not shown","Cofactor requirements for repression undefined"]},{"year":2009,"claim":"Extended ZHX2's repressive role from oncofetal markers to metabolic genes and connected it to a quantitative lipid phenotype.","evidence":"QTL mapping with congenic strains plus transgenic complementation and hepatic microarray in BALB/cJ mice (LPL); Co-IP and functional assays in neural progenitors (ephrin-B1)","pmids":["20160197","19515908"],"confidence":"High","gaps":["Direct LPL promoter occupancy not demonstrated in this work","Mechanism by which ephrin-B1 intracellular domain enhances repression unresolved"]},{"year":2014,"claim":"Demonstrated ZHX2 acts through direct promoter binding and partner transcription factors, clarifying its molecular mode of repression.","evidence":"ChIP and luciferase reporter assays for GPC3 core promoter binding and NF-YA-dependent MDR1 repression with nuclear translocation requirement","pmids":["25195714","25473899"],"confidence":"Medium","gaps":["Genome-wide binding repertoire not defined","Determinants of nuclear translocation unknown at this stage"]},{"year":2018,"claim":"Revealed that ZHX2 protein stability is governed by the VHL E3 ligase, explaining its accumulation and oncogenic co-activator switch in ccRCC.","evidence":"Genome-wide VHL substrate screen, hydroxylation-dependent ubiquitination/stability assays, ChIP-seq, and in vivo tumor growth assays; cccDNA ChIP and miR-155 3'UTR studies for HBV regulation","pmids":["30026228","29580980","29752719"],"confidence":"High","gaps":["Direct co-occupancy with p65 on NF-κB targets not mapped in this study","Hydroxylation site and prolyl hydroxylase identity not fully resolved"]},{"year":2020,"claim":"Showed ZHX2 acts bidirectionally as both repressor and activator across tissues, linking it to metabolism, immunity, and stemness.","evidence":"Myeloid- and liver-specific conditional KO mice with ChIP and genetic rescue for Pfkfb3 activation, miR-24-3p/SREBP1c repression, and KDM2A-mediated stemness control","pmids":["32179636","32770671","32114388","32382017","32780537"],"confidence":"High","gaps":["Molecular switch dictating activator vs repressor mode not defined","How ZHX2 selects activating versus repressing promoters unclear"]},{"year":2021,"claim":"Defined ZHX2 as a HIF1α co-activator in TNBC and a repressor of NK maturation, broadening its transcription-factor partnerships and identifying functionally critical residues.","evidence":"Reciprocal Co-IP, ChIP-seq co-occupancy at active promoters, ZHX2 point mutagenesis (R491/R581/R674); NK-specific conditional KO with Zeb2 target identification","pmids":["34779768","34279541"],"confidence":"High","gaps":["Structural basis of ZHX2-HIF1α interaction unknown","How the same factor partners with both p65 and HIF1α in different cancers unresolved"]},{"year":2022,"claim":"Identified post-translational controls that set ZHX2 abundance and chromatin activity, providing actionable nodes upstream of its function.","evidence":"DUB library screen with ubiquitination/enzymatic-mutant assays (USP13); in vitro Nα-methylation assay and methylation-deficient mutant with promoter occupancy readout (NRMT1)","pmids":["36037364","35613330"],"confidence":"High","gaps":["Interplay between VHL ubiquitination and USP13 deubiquitination not kinetically resolved","Whether N-terminal methylation is regulated dynamically in disease unknown"]},{"year":2023,"claim":"Mapped ZHX2's reach into mitochondrial metabolism, macrophage polarization, β-cell maintenance, and epithelial state, while adding upstream YAP and Hippo control.","evidence":"Conditional KO and injury models with PGC-1α/ETC epistasis; Co-IP/ChIP for p65-Irf1, Pax6, CDH1, Elovl3; Co-IP showing YAP competes with ZHX2 for p65","pmids":["37980429","37582865","37275527","37460540","37847682","40120683"],"confidence":"Medium","gaps":["Unified principle governing tissue-specific repressor/activator output still lacking","PGC-1α destabilization mechanism not molecularly resolved"]},{"year":2025,"claim":"Established a phase-separation mechanism that reframes ZHX2 as a hypoxia-responsive condensate-forming factor coupling chromatin architecture to metastasis, plus an m6A axis controlling its mRNA.","evidence":"LLPS/condensate assays with IDR deletion and S625/S628 phosphosite mutagenesis, CTCF Co-IP in condensates, chromatin-looping ChIP, in vivo metastasis; m6A-RIP/RIP and stability assays (METTL3/IGF2BP1, YTHDF2 loop); LLPS-dependent SLC3A2 activation in DLBCL","pmids":["40185097","39159608","39987125","40730912"],"confidence":"High","gaps":["Kinase responsible for hypoxia-induced S625/S628 phosphorylation not identified","Relationship between condensate formation and classical dimerization/cofactor binding unclear"]},{"year":null,"claim":"The molecular determinant that switches ZHX2 between transcriptional repression and co-activation across tissues remains undefined.","evidence":"No experiment in the corpus isolates the cofactor, modification, or DNA-context rule that toggles ZHX2 output mode","pmids":[],"confidence":"Medium","gaps":["No structure of ZHX2 on DNA or with its partners","No unified model reconciling repressor (liver) and activator (ccRCC/TNBC) functions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,6,10,14,18]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,10,20,22,24]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,6,24]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[29]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,14,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,9,11,18]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,16,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,15,19]}],"complexes":[],"partners":["ZHX3","ZHX1","VHL","USP13","NRMT1","HIF1A","RELA","CTCF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y6X8","full_name":"Zinc fingers and homeoboxes protein 2","aliases":["Alpha-fetoprotein regulator 1","AFP regulator 1","Regulator of AFP","Zinc finger and homeodomain protein 2"],"length_aa":837,"mass_kda":92.3,"function":"Acts as a transcriptional repressor (PubMed:12741956). Represses the promoter activity of the CDC25C gene stimulated by NFYA (PubMed:12741956). May play a role in retinal development where it regulates the composition of bipolar cell populations, by promoting differentiation of bipolar OFF-type cells (By similarity). In the brain, may promote maintenance and suppress differentiation of neural progenitor cells in the developing cortex (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9Y6X8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZHX2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"HDAC1","stoichiometry":0.2},{"gene":"HDAC2","stoichiometry":0.2},{"gene":"RBBP4","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZHX2","total_profiled":1310},"omim":[{"mim_id":"609185","title":"ZINC FINGER AND HOMEODOMAIN PROTEIN 2; ZHX2","url":"https://www.omim.org/entry/609185"},{"mim_id":"141749","title":"FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 1; HBFQTL1","url":"https://www.omim.org/entry/141749"},{"mim_id":"104150","title":"ALPHA-FETOPROTEIN; AFP","url":"https://www.omim.org/entry/104150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZHX2"},"hgnc":{"alias_symbol":["KIAA0854"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y6X8","domains":[{"cath_id":"3.30.160","chopping":"79-157","consensus_level":"medium","plddt":78.1708,"start":79,"end":157},{"cath_id":"1.10.10,1.10.10","chopping":"270-321","consensus_level":"high","plddt":90.966,"start":270,"end":321},{"cath_id":"1.10.10.60","chopping":"449-517","consensus_level":"medium","plddt":87.7625,"start":449,"end":517},{"cath_id":"1.10.10.60","chopping":"539-593","consensus_level":"high","plddt":91.4144,"start":539,"end":593},{"cath_id":"1.10.10.60","chopping":"638-697","consensus_level":"high","plddt":86.9303,"start":638,"end":697}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6X8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6X8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y6X8-F1-predicted_aligned_error_v6.png","plddt_mean":59.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZHX2","jax_strain_url":"https://www.jax.org/strain/search?query=ZHX2"},"sequence":{"accession":"Q9Y6X8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y6X8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y6X8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y6X8"}},"corpus_meta":[{"pmid":"30026228","id":"PMC_30026228","title":"VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30026228","citation_count":159,"is_preprint":false},{"pmid":"15626755","id":"PMC_15626755","title":"Hereditary persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15626755","citation_count":84,"is_preprint":false},{"pmid":"29752719","id":"PMC_29752719","title":"HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29752719","citation_count":58,"is_preprint":false},{"pmid":"31740790","id":"PMC_31740790","title":"Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31740790","citation_count":53,"is_preprint":false},{"pmid":"32114388","id":"PMC_32114388","title":"ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32114388","citation_count":52,"is_preprint":false},{"pmid":"21216289","id":"PMC_21216289","title":"Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer.","date":"2011","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/21216289","citation_count":50,"is_preprint":false},{"pmid":"32179636","id":"PMC_32179636","title":"Zhx2 Accelerates Sepsis by Promoting Macrophage Glycolysis via Pfkfb3.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32179636","citation_count":48,"is_preprint":false},{"pmid":"36037364","id":"PMC_36037364","title":"USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36037364","citation_count":47,"is_preprint":false},{"pmid":"16707376","id":"PMC_16707376","title":"Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma.","date":"2006","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16707376","citation_count":46,"is_preprint":false},{"pmid":"22078940","id":"PMC_22078940","title":"Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma.","date":"2011","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/22078940","citation_count":42,"is_preprint":false},{"pmid":"19515908","id":"PMC_19515908","title":"ZHX2 Interacts with Ephrin-B and regulates neural progenitor maintenance in the developing cerebral cortex.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19515908","citation_count":40,"is_preprint":false},{"pmid":"14659886","id":"PMC_14659886","title":"The mouse zinc-fingers and homeoboxes (ZHX) family; ZHX2 forms a heterodimer with ZHX3.","date":"2003","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/14659886","citation_count":39,"is_preprint":false},{"pmid":"34779768","id":"PMC_34779768","title":"ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34779768","citation_count":38,"is_preprint":false},{"pmid":"32770671","id":"PMC_32770671","title":"ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.","date":"2020","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32770671","citation_count":34,"is_preprint":false},{"pmid":"32382017","id":"PMC_32382017","title":"ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32382017","citation_count":33,"is_preprint":false},{"pmid":"20160197","id":"PMC_20160197","title":"Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism.","date":"2009","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20160197","citation_count":33,"is_preprint":false},{"pmid":"25473899","id":"PMC_25473899","title":"ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25473899","citation_count":32,"is_preprint":false},{"pmid":"25195714","id":"PMC_25195714","title":"Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25195714","citation_count":30,"is_preprint":false},{"pmid":"18353163","id":"PMC_18353163","title":"Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.","date":"2008","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/18353163","citation_count":30,"is_preprint":false},{"pmid":"21987443","id":"PMC_21987443","title":"t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21987443","citation_count":29,"is_preprint":false},{"pmid":"33542193","id":"PMC_33542193","title":"HNRNPD interacts with ZHX2 regulating the vasculogenic mimicry formation of glioma cells via linc00707/miR-651-3p/SP2 axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33542193","citation_count":28,"is_preprint":false},{"pmid":"19273305","id":"PMC_19273305","title":"ZHX2 and ZHX3 repress cancer markers in normal hepatocytes.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273305","citation_count":26,"is_preprint":false},{"pmid":"30026271","id":"PMC_30026271","title":"Transcription Factor Zhx2 Deficiency Reduces Atherosclerosis and Promotes Macrophage Apoptosis in Mice.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30026271","citation_count":25,"is_preprint":false},{"pmid":"29580980","id":"PMC_29580980","title":"Tumor suppressor ZHX2 restricts hepatitis B virus replication via epigenetic and non-epigenetic manners.","date":"2018","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/29580980","citation_count":24,"is_preprint":false},{"pmid":"34279541","id":"PMC_34279541","title":"Transcription factor Zhx2 restricts NK cell maturation and suppresses their antitumor immunity.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34279541","citation_count":22,"is_preprint":false},{"pmid":"37582865","id":"PMC_37582865","title":"Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37582865","citation_count":21,"is_preprint":false},{"pmid":"31683461","id":"PMC_31683461","title":"ZHX2 inhibits proliferation and promotes apoptosis of human lung cancer cells through targeting p38MAPK pathway.","date":"2020","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/31683461","citation_count":19,"is_preprint":false},{"pmid":"37980429","id":"PMC_37980429","title":"ZHX2 emerges as a negative regulator of mitochondrial oxidative phosphorylation during acute liver injury.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37980429","citation_count":18,"is_preprint":false},{"pmid":"40185097","id":"PMC_40185097","title":"Hypoxia-induced phase separation of ZHX2 alters chromatin looping to drive cancer metastasis.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40185097","citation_count":17,"is_preprint":false},{"pmid":"35151335","id":"PMC_35151335","title":"ZHX2 inhibits thyroid cancer metastasis through transcriptional inhibition of S100A14.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/35151335","citation_count":17,"is_preprint":false},{"pmid":"18066620","id":"PMC_18066620","title":"Characterization of the ETnII-alpha endogenous retroviral element in the BALB/cJ Zhx2 ( Afr1 ) allele.","date":"2007","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/18066620","citation_count":17,"is_preprint":false},{"pmid":"20568903","id":"PMC_20568903","title":"Expression of RAN, ZHX-2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors.","date":"2010","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/20568903","citation_count":13,"is_preprint":false},{"pmid":"32059999","id":"PMC_32059999","title":"The zinc fingers and homeoboxes 2 protein ZHX2 and its interacting proteins regulate upstream pathways in podocyte diseases.","date":"2019","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/32059999","citation_count":12,"is_preprint":false},{"pmid":"32780537","id":"PMC_32780537","title":"ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32780537","citation_count":11,"is_preprint":false},{"pmid":"35613330","id":"PMC_35613330","title":"Novel regulation of the transcription factor ZHX2 by N-terminal methylation.","date":"2022","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/35613330","citation_count":11,"is_preprint":false},{"pmid":"31321500","id":"PMC_31321500","title":"Liver size and lipid content differences between BALB/c and BALB/cJ mice on a high-fat diet are due, in part, to Zhx2.","date":"2019","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/31321500","citation_count":11,"is_preprint":false},{"pmid":"35688478","id":"PMC_35688478","title":"Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward.","date":"2022","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35688478","citation_count":10,"is_preprint":false},{"pmid":"36465389","id":"PMC_36465389","title":"ZHX2 in health and disease.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36465389","citation_count":9,"is_preprint":false},{"pmid":"39159608","id":"PMC_39159608","title":"METTL3 and IGF2BP1-Mediated m6A Modification of ZHX2 Promotes Tumor Property of Renal Cell Carcinoma.","date":"2024","source":"Kidney & blood pressure research","url":"https://pubmed.ncbi.nlm.nih.gov/39159608","citation_count":9,"is_preprint":false},{"pmid":"39987125","id":"PMC_39987125","title":"ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2.","date":"2025","source":"Nutrition & diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/39987125","citation_count":8,"is_preprint":false},{"pmid":"40120683","id":"PMC_40120683","title":"The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40120683","citation_count":6,"is_preprint":false},{"pmid":"37563132","id":"PMC_37563132","title":"Characterization of circSEC11A as a novel regulator of Iodine-125 radioactive seed-induced anticancer effects in hepatocellular carcinoma via targeting ZHX2/GADD34 axis.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37563132","citation_count":5,"is_preprint":false},{"pmid":"40730912","id":"PMC_40730912","title":"Liquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2.","date":"2025","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/40730912","citation_count":4,"is_preprint":false},{"pmid":"37460540","id":"PMC_37460540","title":"ZHX2 deficiency enriches hybrid MET cells through regulating E-cadherin expression.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37460540","citation_count":4,"is_preprint":false},{"pmid":"30146259","id":"PMC_30146259","title":"The role of Zhx2 transcription factor in bipolar cell differentiation during mouse retinal development.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30146259","citation_count":4,"is_preprint":false},{"pmid":"37275527","id":"PMC_37275527","title":"Zhx2 maintains islet β-cell mass and function by transcriptionally regulating Pax6.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37275527","citation_count":3,"is_preprint":false},{"pmid":"39492517","id":"PMC_39492517","title":"An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patients.","date":"2023","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/39492517","citation_count":3,"is_preprint":false},{"pmid":"21443521","id":"PMC_21443521","title":"Lack of association of G779A ZHX-2 gene variant with HbF levels in β-thalassemia major.","date":"2011","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/21443521","citation_count":3,"is_preprint":false},{"pmid":"40215834","id":"PMC_40215834","title":"Validation studies and multiomics analysis of Zhx2 as a candidate quantitative trait gene underlying brain oxycodone metabolite (oxymorphone) levels and behavior.","date":"2025","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/40215834","citation_count":2,"is_preprint":false},{"pmid":"30784286","id":"PMC_30784286","title":"Targeting genes and signaling pathways of transcriptional suppressor ZHX2 in hepatocellular carcinoma: a Chromatin Immunoprecipitation-sequencing (ChIP-seq) investigation.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30784286","citation_count":2,"is_preprint":false},{"pmid":"37847682","id":"PMC_37847682","title":"Elongation of very long chain fatty acids-3 (Elovl3) is activated by ZHX2 and is a regulator of cell cycle progression.","date":"2023","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37847682","citation_count":1,"is_preprint":false},{"pmid":"38201462","id":"PMC_38201462","title":"Sunitinib Treatment of VHL C162F Cells Slows Down Proliferation and Healing Ability via Downregulation of ZHX2 and Confers a Mesenchymal Phenotype.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38201462","citation_count":1,"is_preprint":false},{"pmid":"39850947","id":"PMC_39850947","title":"Relationship between ZHX2 Expression and VHL Gene Alteration in VHL-associated and Sporadic Hemangioblastomas of the Central Nervous System.","date":"2024","source":"Journal of kidney cancer and VHL","url":"https://pubmed.ncbi.nlm.nih.gov/39850947","citation_count":0,"is_preprint":false},{"pmid":"40991982","id":"PMC_40991982","title":"Molecular mechanisms underlying the oncogenic and tumor-suppressive roles of ZHX2 in cancers.","date":"2025","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40991982","citation_count":0,"is_preprint":false},{"pmid":"39257803","id":"PMC_39257803","title":"Validation studies and multi-omics analysis of Zhx2 as a candidate quantitative trait gene underlying brain oxycodone metabolite (oxymorphone) levels and behavior.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39257803","citation_count":0,"is_preprint":false},{"pmid":"38979373","id":"PMC_38979373","title":"The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38979373","citation_count":0,"is_preprint":false},{"pmid":"42070457","id":"PMC_42070457","title":"Transcription factor zinc fingers and homeoboxes protein 2 (ZHX2) drives CRABP1 targeting to strengthen retinoic acid sensitivity and potentiate therapeutic response in neuroblastoma.","date":"2026","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/42070457","citation_count":0,"is_preprint":false},{"pmid":"31511211","id":"PMC_31511211","title":"[Role of ZHX2 in regulating dorsal root ganglion μ-opioid receptor expression in mice with peripheral nerve injuryinduced pain hypersensitivity].","date":"2019","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/31511211","citation_count":0,"is_preprint":false},{"pmid":"41603587","id":"PMC_41603587","title":"GMSCs-Derived Exosome ZHX2 Improves Diabetes Nephropathy by Blocking AGEs/RAGE/NLRP3 Pathway to Inhibit Podocyte Pyroptosis and Inflammatory Response.","date":"2026","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/41603587","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.11.619598","title":"Identification of methylation-sensitive human transcription factors using meSMiLE-seq","date":"2024-11-12","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.11.619598","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32710,"output_tokens":9985,"usd":0.123952,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20439,"output_tokens":4086,"usd":0.102172,"stage2_stop_reason":"end_turn"},"total_usd":0.226124,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"ZHX2 (Afr1) functions as a transcriptional repressor responsible for postnatal silencing of alpha-fetoprotein (AFP) and H19 in the liver. Liver-specific overexpression of a Zhx2 transgene in BALB/cJ mice (which carry a retroviral insertion disrupting Zhx2) restored wild-type H19 repression, directly demonstrating that Zhx2 is the gene responsible for hereditary persistence of AFP and H19.\",\n      \"method\": \"Transgenic complementation in BALB/cJ mice with liver-specific Zhx2 overexpression; positional cloning/mapping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic rescue experiment with clear functional readout, replicated in subsequent studies from multiple labs\",\n      \"pmids\": [\"15626755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ZHX2 forms a heterodimer with ZHX3 via a region containing homeodomain 1 (HD1), demonstrated by in vitro and in vivo protein-protein interaction assays. ZHX family members (ZHX1, ZHX2, ZHX3) act as ubiquitous transcriptional repressors and can form both homodimers and heterodimers.\",\n      \"method\": \"In vitro and in vivo protein-protein interaction assays (co-immunoprecipitation/pull-down); cDNA cloning and expression analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct protein-protein interaction assays in one study, consistent with family-level characterization\",\n      \"pmids\": [\"14659886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZHX2 is expressed specifically in neural progenitor cells during cortical neurogenesis and binds to the cytoplasmic domain of ephrin-B1. ZHX2 acts as a transcriptional repressor, and its repressor activity is enhanced by co-expression with the ephrin-B1 intracellular domain. Blocking ZHX2 function causes neuronal differentiation, while overexpression of ZHX2 with ephrin-B1 intracellular domain disrupts normal differentiation of cortical neural progenitor cells.\",\n      \"method\": \"Co-immunoprecipitation (ZHX2 binding ephrin-B1); loss-of-function and gain-of-function in cultured neural progenitor cells and embryonic cortex; transcriptional repressor assay\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct binding shown by Co-IP, loss- and gain-of-function with defined phenotype, single lab\",\n      \"pmids\": [\"19515908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Zhx2 functions as a novel developmental regulator of hepatic lipoprotein metabolism. Reduced Zhx2 expression in BALB/cJ mice causes failure to suppress lipoprotein lipase (LPL) expression in adult liver, a gene normally silenced postnatally; Zhx2 transgene in BALB/cJ mice normalized hepatic LPL expression. QTL mapping and transgenic complementation identified Zhx2 as the gene underlying a chromosome 15 QTL for HDL cholesterol and triglyceride levels.\",\n      \"method\": \"QTL mapping with congenic strains; transgenic complementation; microarray analysis of hepatic gene expression\",\n      \"journal\": \"Circulation. Cardiovascular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — QTL fine-mapping combined with transgenic rescue and gene expression analysis, replicates findings from the Spear lab\",\n      \"pmids\": [\"20160197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZHX2 is a substrate of the VHL E3 ubiquitin ligase complex: VHL regulates ZHX2 protein stability via hydroxylation-dependent ubiquitination. Loss of VHL in ccRCC leads to increased ZHX2 abundance and nuclear localization. ZHX2 promotes NF-κB activation in ccRCC, as demonstrated by integrated ChIP-seq and microarray analysis, and ZHX2 depletion inhibits VHL-deficient ccRCC cell growth in vitro and in vivo.\",\n      \"method\": \"Genome-wide in vitro expression/binding screen for VHL substrates; protein stability assays; ChIP-seq; microarray; in vitro and in vivo tumor growth assays (knockdown)\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (binding screen, stability assay, ChIP-seq, in vivo), highly cited, independently followed up\",\n      \"pmids\": [\"30026228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZHX2 represses MDR1 (multidrug resistance 1) transcription by interacting with NF-YA and reducing NF-Y binding to the MDR1 promoter. Co-IP and ChIP assays showed ZHX2 physically interacts with NF-YA; luciferase reporter assays showed ZHX2-mediated repression of MDR1 promoter is abolished by NF-YA knockdown or mutation of the NF-Y binding site. Increased ZHX2 enhances chemosensitivity in HCC cells in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation; ChIP assay; luciferase reporter assay; in vitro drug sensitivity assays; in vivo xenograft\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal Co-IP and ChIP with functional reporter validation, single lab\",\n      \"pmids\": [\"25473899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZHX2 directly binds the core promoter of GPC3 (glypican 3) and suppresses its transcription. Nuclear translocation of ZHX2 is required for this repression. Loss of nuclear ZHX2 in HCC is responsible for GPC3 reactivation.\",\n      \"method\": \"Dual luciferase reporter assay; ChIP assay; ZHX2 overexpression/knockdown in HCC cell lines; immunohistochemistry; nuclear translocation experiments\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and luciferase reporter with nuclear localization requirement established, single lab\",\n      \"pmids\": [\"25195714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZHX2 restricts HBV replication by binding to HBV cccDNA and transcriptionally inhibiting HBV promoter activities. ZHX2 also suppresses expression of histone regulator genes including p300/CBP that bind cccDNA, leading to epigenetic repression of cccDNA transcription.\",\n      \"method\": \"Dual luciferase assay; cccDNA ChIP assay; ZHX2 overexpression/knockdown in vitro and in mouse liver models; immunohistochemistry; measurement of HBV antigens and DNA\",\n      \"journal\": \"Antiviral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — cccDNA ChIP directly demonstrates binding, multiple readouts, single lab\",\n      \"pmids\": [\"29580980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HBV X protein (HBx) inhibits ZHX2 expression via upregulation of miR-155, which targets the ZHX2 3'UTR. miR-155 overexpression reduced ZHX2 levels through its seed sites in the ZHX2 3'UTR, and blocking miR-155 increased ZHX2 levels. This pathway links HBV oncogenic properties to ZHX2 suppression.\",\n      \"method\": \"miR-155 overexpression/blockade experiments; 3'UTR reporter assay; in vitro and in vivo HBV/HBx overexpression models; qPCR and Western blot\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — 3'UTR reporter and miRNA blockade experiments across in vitro and in vivo models, single lab\",\n      \"pmids\": [\"29752719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZHX2 inhibits lipid uptake in hepatocytes by transcriptionally suppressing lipoprotein lipase (LPL). ZHX2 overexpression decreased LPL transcription, inhibited exogenous lipid uptake, and reduced HCC cell proliferation; LPL overexpression reversed ZHX2-mediated inhibition. ZHX2 and LPL show inverse correlation in HCC patient samples.\",\n      \"method\": \"ZHX2 overexpression/knockdown in HCC cell lines; in vitro and in vivo lipid uptake assays; LPL rescue overexpression; xenograft tumor growth; IHC in patient cohort\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — epistasis rescue experiment (LPL reversal), in vivo xenograft, IHC correlation, single lab\",\n      \"pmids\": [\"31740790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZHX2 enhances macrophage glycolysis and promotes sepsis pathogenesis by directly binding to the Pfkfb3 promoter and enhancing Pfkfb3 transcription. Myeloid-specific Zhx2 deletion reduced Pfkfb3 expression and macrophage glycolytic rate; Pfkfb3 overexpression rescued the glycolysis defect caused by Zhx2 deficiency. This was demonstrated by RNA-seq and ChIP assays.\",\n      \"method\": \"Myeloid-specific conditional knockout mice; RNA sequencing; ChIP assay (Zhx2 binding Pfkfb3 promoter); Pfkfb3 rescue overexpression; extracellular acidification rate and lactate measurement; cecal ligation and puncture (CLP) and LPS sepsis models\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with genetic rescue, direct ChIP evidence of promoter binding, in vivo and in vitro mechanistic chain, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"32179636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZHX2 suppresses HCC progression by inhibiting de novo lipogenesis via transcriptional upregulation of miR-24-3p, which targets and promotes degradation of SREBP1c. ZHX2 overexpression reduced FASN, ACL, ACC1, and SCD1; ZHX2-mediated effects were reversed by SREBP1c overexpression; liver-specific Zhx2 KO mice showed increased spontaneous tumor formation reversed by SREBP1c inhibitor fatostatin.\",\n      \"method\": \"ZHX2 overexpression/knockdown in HCC cells; miR-24-3p rescue/inhibition; SREBP1c overexpression rescue; Zhx2 liver-specific knockout mice; fatostatin treatment; qPCR and Western blot\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vivo KO model with genetic epistasis (fatostatin rescue), miRNA mechanism validated, single lab\",\n      \"pmids\": [\"32770671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZHX2 suppresses liver cancer stem cell (CSC) traits by transcriptionally repressing KDM2A (a histone H3K36 demethylase). ZHX2 inhibits KDM2A-mediated demethylation of H3K36 at promoters of stemness transcription factors NANOG, SOX4, and OCT4, thereby restricting CSC self-renewal, tumor initiation, and sorafenib resistance. This was demonstrated by microarray, luciferase reporter, ChIP, and ChIP-on-chip analyses.\",\n      \"method\": \"ChIP; ChIP-on-chip; luciferase reporter assay; microarray; ZHX2 overexpression/knockdown in sorted CSC populations; in vivo tumor initiation assays\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP-on-chip and ChIP directly link ZHX2 to KDM2A promoter, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"32114388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZHX2 overexpression drives ccRCC cell growth and migration through transcriptional activation of MEK/ERK1/2 signaling and its downstream targets, and also increases VEGF secretion. ZHX2 overexpression induces sunitinib resistance through activating autophagy.\",\n      \"method\": \"Lentiviral overexpression/knockdown in VHL-deficient (786-O) and VHL-normal (CAKI-1) cell lines; in vitro and in vivo growth/migration assays; Western blot for MEK/ERK pathway; autophagic flux measurement; drug sensitivity assay with chloroquine rescue\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, primarily overexpression/knockdown without direct transcriptional binding evidence for MEK/ERK pathway activation\",\n      \"pmids\": [\"32382017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZHX2 physically interacts with HIF family members (HIF1α) and positively regulates HIF1α transcriptional activity in triple-negative breast cancer (TNBC). ZHX2 and HIF1α co-occupy transcriptionally active promoters marked by H3K4me3 and H3K27ac, as shown by integrated ChIP-seq and gene expression profiling. Residues R491, R581, and R674 on ZHX2 are important for its transcriptional activity and oncogenic phenotype in TNBC.\",\n      \"method\": \"Co-immunoprecipitation (ZHX2-HIF1α); ChIP-seq; gene expression profiling; ZHX2 point mutant analysis; ZHX2 knockdown with in vitro and in vivo tumor growth assays; rescue by overexpression of target genes\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP-seq, functional mutagenesis of ZHX2 residues, in vitro and in vivo models, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"34779768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZHX2 transcriptionally represses Zeb2 (a key transcription factor for NK cell terminal maturation) in NK cells, thereby restricting NK cell maturation and survival. Conditional deletion of Zhx2 in NK cells resulted in accumulation of mature NK cells and enhanced NK cell response to IL-15, with Zeb2 identified as a direct downstream target.\",\n      \"method\": \"NK cell-specific conditional Zhx2 knockout mice; transcriptomic analysis; in vivo tumor models with Zhx2-deficient NK cell transfer; assessment of NK cell maturation markers\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with transcriptomic target identification, in vivo functional assay, single lab\",\n      \"pmids\": [\"34279541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP13 is a deubiquitinase (DUB) that binds ZHX2 and promotes ZHX2 deubiquitination and protein stability in an enzymatically dependent manner. USP13 depletion leads to ZHX2 downregulation in ccRCC and decreased tumor cell proliferation in vitro and in vivo; the effect of USP13 on ccRCC growth is partially mediated through ZHX2.\",\n      \"method\": \"DUB cDNA library binding screen; co-immunoprecipitation (USP13-ZHX2); ubiquitination assay; enzymatic mutant USP13 analysis; 2D colony formation and 3D anchorage-independent growth assays; in vivo tumor growth\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — DUB screen followed by Co-IP, ubiquitination assay, enzymatic mutant validation, in vitro and in vivo functional assays, rigorous multi-method study\",\n      \"pmids\": [\"36037364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZHX2 is a substrate for N-terminal methylation (Nα-methylation) by the methyltransferase NRMT1. NRMT1 can methylate ZHX2 in vitro, and a methylation-deficient ZHX2 mutant shows reduced transcription factor activity and reduced promoter occupancy. Loss of NRMT1 in mice causes dysregulation of ZHX2 targets (CYP and MUP families) in liver, linking NRMT1-mediated Nα-methylation to ZHX2 function.\",\n      \"method\": \"In vitro methylation assay (NRMT1 + ZHX2); methylation-deficient ZHX2 mutant analysis; RNA-seq of NRMT1 knockout mouse livers; promoter occupancy assay; Western blot and qPCR\",\n      \"journal\": \"Transcription\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro methylation assay and methylation-deficient mutant with functional readout, single lab\",\n      \"pmids\": [\"35613330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 is a negative regulator of mitochondrial oxidative phosphorylation (OXPHOS) during acute liver injury. ZHX2 both transcriptionally inhibits expression of mitochondrial electron transport chain genes and decreases PGC-1α protein stability, leading to reduced mitochondrial mass and OXPHOS. Loss of Zhx2 promotes liver recovery after partial hepatectomy or CCl4 injury by increasing mitochondrial OXPHOS; inhibition of PGC-1α or ETC abolishes these protective effects.\",\n      \"method\": \"Conditional Zhx2 knockout mice; partial hepatectomy and CCl4 liver injury models; measurement of mitochondrial mass and OXPHOS; transcriptional analysis of ETC genes; PGC-1α stability assay; shRNA delivery in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo with epistasis rescue (PGC-1α/ETC inhibition abolishes effect), two injury models, multiple mechanistic arms, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"37980429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 associates with NF-κB p65 and binds to the Irf1 promoter to transcriptionally activate Irf1 in macrophages, thereby controlling macrophage polarization. Myeloid-specific Zhx2 deletion suppresses LPS-induced proinflammatory polarization but promotes IL-4- and tumor microenvironment-induced pro-tumoral macrophage phenotype. Lactate from the tumor microenvironment decreases Zhx2 expression, leading to a switch toward pro-tumor TAM phenotype.\",\n      \"method\": \"Myeloid-specific Zhx2 conditional KO mice; co-immunoprecipitation (ZHX2-p65); ChIP/reporter assay (Irf1 promoter); murine liver tumor models; macrophage polarization assays; Western blot\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP for mechanism, conditional KO with functional phenotype, single lab\",\n      \"pmids\": [\"37582865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 transcriptionally activates Pax6 by binding to the Pax6 promoter region (positions -1740 to -1563, -862 to -559, and -251 to +75). β-cell-specific Zhx2 knockout mice showed decreased β-cell proliferation, reduced β-cell mass, and impaired glucose homeostasis, demonstrating a role for Zhx2 in maintaining β-cell mass and function via Pax6 regulation.\",\n      \"method\": \"β-cell-specific Zhx2 knockout mice; ChIP assay (Zhx2 binding Pax6 promoter); luciferase reporter assay; glucose tolerance tests; insulin secretion measurements\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and reporter assay with tissue-specific KO mouse model, single lab\",\n      \"pmids\": [\"37275527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 transcriptionally inhibits GADD34 expression by binding to its promoter, thereby enhancing endoplasmic reticulum stress-mediated anticancer effects of I-125 radiation in HCC. This was part of a circSEC11A/miR-3529-3p/ZHX2/GADD34 axis.\",\n      \"method\": \"Dual-luciferase reporter assay; RNA pull-down; RNA immunoprecipitation; FISH; in vitro and in vivo anticancer effect assays (CCK-8, flow cytometry, TUNEL, EdU, transwell)\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mechanistic assignment of ZHX2 binding GADD34 promoter supported by reporter assay, but single lab, limited direct ChIP evidence described\",\n      \"pmids\": [\"37563132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 directly binds the CDH1 promoter and represses E-cadherin (CDH1) expression in TNBC cells. Loss of ZHX2 reactivates CDH1, promoting a hybrid mesenchymal-to-epithelial (MET) state and inhibiting cancer cell migration and metastasis. E-cadherin restoration reverses the effects of ZHX2 loss.\",\n      \"method\": \"ChIP assay (ZHX2 binding CDH1 promoter); ZHX2 knockdown/overexpression; CDH1 rescue overexpression; cell migration assays; in vivo lung metastasis models; organoid culture\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP evidence with functional rescue experiment, in vivo metastasis model, single lab\",\n      \"pmids\": [\"37460540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZHX2 positively regulates Elovl3 expression in the liver by directly activating its transcription. Zhx2 loss-of-function in mice reduces Elovl3 levels; Elovl3 expression is repressed during liver regeneration correlating with reduced very long chain fatty acids. Forced Elovl3 expression in human hepatoma cells reduces cell growth and blocks cell cycle progression in S-phase.\",\n      \"method\": \"Mouse models of Zhx2 loss-of-function; liver regeneration models (partial hepatectomy, CCl4); cell growth assays; cell cycle synchronization; mRNA and protein analysis; VLCFA measurements\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mouse models and cell-based rescue experiment, direct ZHX2-Elovl3 regulatory axis defined, single lab\",\n      \"pmids\": [\"37847682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZHX2 undergoes liquid-liquid phase separation (LLPS) in response to hypoxia via a proline-rich intrinsically disordered region (IDR), which enhances chromatin occupancy. Hypoxia induces phosphorylation of ZHX2 at S625 and S628, incorporating CTCF into ZHX2 condensates and altering chromatin looping to activate metastatic gene transcription. This phase separation drives cancer metastasis in breast cancer cells and is distinct from HIF-dependent hypoxia responses.\",\n      \"method\": \"Phase separation/condensate formation assays; phosphorylation site identification and mutagenesis (S625, S628); CTCF co-immunoprecipitation in condensates; ChIP for chromatin looping; in vivo metastasis models; IDR deletion mutants\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — phase separation reconstitution with mutagenesis of critical phosphosites, CTCF Co-IP in condensates, chromatin looping ChIP, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"40185097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"YAP (Hippo pathway effector) inhibits ZHX2 expression and competes with ZHX2 for binding to the NF-κB subunit p65. Elevated nuclear YAP blocks the cooperative interaction between ZHX2 and p65, leading to diminished NF-κB target gene expression and suppressed ccRCC cell growth. ZHX2 overexpression or p65 overexpression rescues the anti-proliferative effects of Hippo kinase inhibition.\",\n      \"method\": \"ZHX2 and p65 co-immunoprecipitation; YAP knockdown/overexpression; pharmacological Hippo kinase inhibition; ZHX2 and p65 overexpression rescue assays; NF-κB target gene expression analysis; ccRCC cell growth assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP showing competitive binding, genetic rescue experiments, single lab\",\n      \"pmids\": [\"40120683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZHX2 undergoes LLPS and binds to the SLC3A2 promoter through phase separation, activating SLC3A2 transcription to inhibit ferroptosis in DLBCL cells. ZHX2-siRNA lipid nanoparticles targeting this mechanism suppressed DLBCL tumor growth in vivo.\",\n      \"method\": \"LLPS assays; ChIP assay (ZHX2 binding SLC3A2 promoter); ZHX2 knockdown/overexpression; ferroptosis assays; in vivo tumor growth with siRNA-LNP\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — LLPS assay with ChIP promoter binding and in vivo functional validation, single lab\",\n      \"pmids\": [\"40730912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL3-mediated m6A methylation of ZHX2 mRNA is recognized by the m6A reader IGF2BP1, which stabilizes ZHX2 mRNA. This m6A modification promotes ZHX2 expression and renal cell carcinoma progression. METTL3 silencing reduces ZHX2, and ZHX2 overexpression reverses the inhibitory effects of METTL3 depletion on RCC tumor growth.\",\n      \"method\": \"m6A RNA immunoprecipitation assay; RNA immunoprecipitation (IGF2BP1-ZHX2 mRNA); mRNA stability assay (Actinomycin D); METTL3 knockdown; ZHX2 overexpression rescue; xenograft mouse model\",\n      \"journal\": \"Kidney & blood pressure research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct m6A-RIP and RIP assays with stability measurement and in vivo rescue, single lab\",\n      \"pmids\": [\"39159608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZHX2 transcriptionally inhibits YTHDF2 by binding to its promoter region, and in turn YTHDF2 recognizes m6A-modified ZHX2 mRNA to promote its degradation, forming a feedback regulatory loop. ZHX2 overexpression protects against diabetes-induced hepatic ferroptosis by suppressing YTHDF2, which otherwise promotes GPX4 and SLC7A11 degradation.\",\n      \"method\": \"Luciferase reporter assay; ChIP assay (ZHX2 at YTHDF2 promoter); RNA immunoprecipitation (YTHDF2 binding ZHX2 mRNA); ZHX2 knockdown/overexpression; in vivo HFD/STZ diabetes mouse model; ferroptosis assays\",\n      \"journal\": \"Nutrition & diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP, luciferase reporter and RIP for two regulatory directions, in vivo model, single lab\",\n      \"pmids\": [\"39987125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZHX2 and ZHX3 form heterodimeric complexes in podocytes, with ZHX2-ZHX1 localized predominantly at the podocyte cell body membrane and ZHX2-ZHX3 at the slit diaphragm. ZHX2 interacts with aminopeptidase A (ENPEP) at the cell body membrane and with ephrin-B1 (EFNB1) at the slit diaphragm, as shown by co-immunoprecipitation. ZHX2 imbalance is a critical factor in glomerular diseases, with ZHX2 sequestering ZHX1 peripherally to regulate its nuclear access.\",\n      \"method\": \"Co-immunoprecipitation (ZHX2 with aminopeptidase A and ephrin-B1); subcellular fractionation/localization; Zhx2 knockout mice; podocyte-specific Zhx2 overexpressing transgenic rats; glomerular disease models; immunofluorescence\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for protein interactions, in vivo transgenic models with functional phenotype, localization experiments, single lab\",\n      \"pmids\": [\"32059999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZHX2 mediates proteasome inhibitor (bortezomib) resistance in multiple myeloma cells by directly binding NF-κB and promoting nuclear translocation of NF-κB. ZHX2 knockdown reduced nuclear NF-κB, decreased NF-κB target gene expression, and enhanced bortezomib sensitivity in myeloma cell lines.\",\n      \"method\": \"Co-immunoprecipitation (ZHX2-NF-κB); Western blot and immunofluorescence for NF-κB nuclear localization; ZHX2 knockdown; flow cytometry for apoptosis; qRT-PCR for NF-κB target genes\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP for ZHX2-NF-κB interaction, single lab, limited mechanistic depth\",\n      \"pmids\": [\"32780537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZHX2 transcriptionally represses S100A14 by binding to its promoter, inhibiting thyroid cancer cell migration and metastasis. S100A14 knockdown reverses ZHX2 depletion-induced enhanced metastasis.\",\n      \"method\": \"ChIP assay (ZHX2 at S100A14 promoter); ZHX2 knockdown/overexpression; S100A14 knockdown rescue; cell migration assays; in vivo lung metastasis model\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and rescue experiment supporting the mechanism, single lab\",\n      \"pmids\": [\"35151335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZHX2 transcriptionally represses CRABP1 by binding to its promoter, which modulates retinoid metabolism and enhances retinoic acid (RA) sensitivity in neuroblastoma cells. ZHX2 overexpression inhibited NB malignancy and augmented RA-induced neuronal differentiation in vitro and reduced tumor growth in vivo.\",\n      \"method\": \"CHIP-qPCR (ZHX2 at CRABP1 promoter); ZHX2 knockdown/overexpression; RNA-seq; cell proliferation, migration, apoptosis assays; in vivo xenograft; differentiation marker analysis\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP-qPCR with functional assays, single lab, published 2026 with limited independent validation\",\n      \"pmids\": [\"42070457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZHX2 knockdown in dorsal root ganglion (DRG) neurons reverses CCI (chronic constriction injury)-induced downregulation of μ-opioid receptor expression and alleviates mechanical allodynia in mice. In primary DRG neurons, ZHX2 knockdown upregulated μ-opioid receptor mRNA and protein, indicating ZHX2 represses μ-opioid receptor expression in DRG neurons.\",\n      \"method\": \"In vivo siRNA microinjection into DRG; RT-qPCR and Western blot for μ-opioid receptor; behavioral testing (paw withdrawal frequency); primary DRG neuron culture with ZHX2 siRNA transfection\",\n      \"journal\": \"Nan fang yi ke da xue xue bao = Journal of Southern Medical University\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, siRNA knockdown without direct promoter binding evidence, limited mechanistic depth\",\n      \"pmids\": [\"31511211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZHX2 transcriptionally inhibits FABP4 by binding to its promoter region, thereby blocking the AGEs/RAGE/NLRP3 pathway and inhibiting podocyte pyroptosis and inflammation in diabetic nephropathy.\",\n      \"method\": \"ChIP assay (ZHX2 at FABP4 promoter); luciferase reporter assay; ZHX2 overexpression/knockdown; in vitro high-glucose podocyte model; in vivo diabetic nephropathy mouse model; exosome delivery of ZHX2\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and reporter assay supporting FABP4 as direct target, single lab, published 2026 with no independent replication\",\n      \"pmids\": [\"41603587\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZHX2 is a multi-context transcription factor that contains zinc-finger and homeodomain motifs, forms homodimers and heterodimers (with ZHX1 and ZHX3), and functions primarily as a transcriptional repressor in the liver (silencing AFP, H19, GPC3, LPL, SREBP1c, MDR1, Pfkfb3 [in macrophages], and mitochondrial ETC genes) but acts as a co-activator in ccRCC and TNBC by binding NF-κB p65 and HIF1α, respectively; its protein stability is regulated by VHL-mediated hydroxylation-dependent ubiquitination and by USP13-mediated deubiquitination, its activity is modulated by NRMT1-catalyzed N-terminal methylation that promotes promoter occupancy, and under hypoxia it undergoes phase separation via a proline-rich IDR with phosphorylation at S625/S628 recruiting CTCF to alter chromatin looping and drive oncogenic metastatic gene transcription.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZHX2 is a zinc-finger/homeodomain transcription factor that acts predominantly as a sequence-specific repressor of a developmentally silenced gene program in the liver while functioning as a context-dependent co-activator in cancer [#0, #4]. It was originally identified as the gene responsible for hereditary persistence of alpha-fetoprotein and H19, with liver-specific transgenic complementation restoring postnatal silencing of these loci [#0], and it likewise enforces postnatal repression of lipoprotein lipase to control hepatic lipoprotein metabolism [#3]. As a repressor it directly binds target promoters (GPC3, MDR1 via NF-YA, mitochondrial ETC genes) and additionally tunes lipid metabolism by driving miR-24-3p-mediated SREBP1c degradation and by destabilizing PGC-1\\u03b1, thereby restraining de novo lipogenesis and mitochondrial OXPHOS [#5, #6, #11, #18]. In clear-cell renal carcinoma ZHX2 switches to an oncogenic co-activator: VHL normally targets it for hydroxylation-dependent ubiquitination, so VHL loss stabilizes and nuclearizes ZHX2, which then associates with NF-\\u03baB p65 to activate NF-\\u03baB target genes [#4]. ZHX2 protein abundance is opposed by USP13-mediated deubiquitination [#16], its promoter occupancy depends on NRMT1-catalyzed N-terminal methylation [#17], and YAP both suppresses its expression and competes for p65 binding [#25]. Under hypoxia ZHX2 undergoes liquid-liquid phase separation through a proline-rich intrinsically disordered region, and phosphorylation at S625/S628 recruits CTCF into condensates to remodel chromatin looping and drive metastatic transcription [#24]. Beyond transcription, ZHX2 forms homo- and heterodimers with ZHX1 and ZHX3 [#1], and in immune and metabolic settings controls macrophage glycolysis and polarization (Pfkfb3, Irf1/p65), NK cell maturation (Zeb2), and \\u03b2-cell mass (Pax6) [#10, #19, #15, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established that ZHX2 is a member of a family of dimerizing transcriptional repressors, defining its structural basis for action before its physiological targets were known.\",\n      \"evidence\": \"cDNA cloning with in vitro and in vivo protein-protein interaction assays showing ZHX2-ZHX3 heterodimerization via HD1\",\n      \"pmids\": [\"14659886\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No target genes or promoter specificity defined\", \"Functional consequence of heterodimerization on repression not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified ZHX2 as the causal gene for hereditary persistence of AFP/H19, answering what enforces postnatal silencing of fetal liver genes.\",\n      \"evidence\": \"Positional cloning and liver-specific Zhx2 transgenic complementation in BALB/cJ mice\",\n      \"pmids\": [\"15626755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter binding to AFP/H19 not shown\", \"Cofactor requirements for repression undefined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended ZHX2's repressive role from oncofetal markers to metabolic genes and connected it to a quantitative lipid phenotype.\",\n      \"evidence\": \"QTL mapping with congenic strains plus transgenic complementation and hepatic microarray in BALB/cJ mice (LPL); Co-IP and functional assays in neural progenitors (ephrin-B1)\",\n      \"pmids\": [\"20160197\", \"19515908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LPL promoter occupancy not demonstrated in this work\", \"Mechanism by which ephrin-B1 intracellular domain enhances repression unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated ZHX2 acts through direct promoter binding and partner transcription factors, clarifying its molecular mode of repression.\",\n      \"evidence\": \"ChIP and luciferase reporter assays for GPC3 core promoter binding and NF-YA-dependent MDR1 repression with nuclear translocation requirement\",\n      \"pmids\": [\"25195714\", \"25473899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide binding repertoire not defined\", \"Determinants of nuclear translocation unknown at this stage\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed that ZHX2 protein stability is governed by the VHL E3 ligase, explaining its accumulation and oncogenic co-activator switch in ccRCC.\",\n      \"evidence\": \"Genome-wide VHL substrate screen, hydroxylation-dependent ubiquitination/stability assays, ChIP-seq, and in vivo tumor growth assays; cccDNA ChIP and miR-155 3'UTR studies for HBV regulation\",\n      \"pmids\": [\"30026228\", \"29580980\", \"29752719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct co-occupancy with p65 on NF-\\u03baB targets not mapped in this study\", \"Hydroxylation site and prolyl hydroxylase identity not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed ZHX2 acts bidirectionally as both repressor and activator across tissues, linking it to metabolism, immunity, and stemness.\",\n      \"evidence\": \"Myeloid- and liver-specific conditional KO mice with ChIP and genetic rescue for Pfkfb3 activation, miR-24-3p/SREBP1c repression, and KDM2A-mediated stemness control\",\n      \"pmids\": [\"32179636\", \"32770671\", \"32114388\", \"32382017\", \"32780537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular switch dictating activator vs repressor mode not defined\", \"How ZHX2 selects activating versus repressing promoters unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined ZHX2 as a HIF1\\u03b1 co-activator in TNBC and a repressor of NK maturation, broadening its transcription-factor partnerships and identifying functionally critical residues.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP-seq co-occupancy at active promoters, ZHX2 point mutagenesis (R491/R581/R674); NK-specific conditional KO with Zeb2 target identification\",\n      \"pmids\": [\"34779768\", \"34279541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ZHX2-HIF1\\u03b1 interaction unknown\", \"How the same factor partners with both p65 and HIF1\\u03b1 in different cancers unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified post-translational controls that set ZHX2 abundance and chromatin activity, providing actionable nodes upstream of its function.\",\n      \"evidence\": \"DUB library screen with ubiquitination/enzymatic-mutant assays (USP13); in vitro N\\u03b1-methylation assay and methylation-deficient mutant with promoter occupancy readout (NRMT1)\",\n      \"pmids\": [\"36037364\", \"35613330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between VHL ubiquitination and USP13 deubiquitination not kinetically resolved\", \"Whether N-terminal methylation is regulated dynamically in disease unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Mapped ZHX2's reach into mitochondrial metabolism, macrophage polarization, \\u03b2-cell maintenance, and epithelial state, while adding upstream YAP and Hippo control.\",\n      \"evidence\": \"Conditional KO and injury models with PGC-1\\u03b1/ETC epistasis; Co-IP/ChIP for p65-Irf1, Pax6, CDH1, Elovl3; Co-IP showing YAP competes with ZHX2 for p65\",\n      \"pmids\": [\"37980429\", \"37582865\", \"37275527\", \"37460540\", \"37847682\", \"40120683\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Unified principle governing tissue-specific repressor/activator output still lacking\", \"PGC-1\\u03b1 destabilization mechanism not molecularly resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established a phase-separation mechanism that reframes ZHX2 as a hypoxia-responsive condensate-forming factor coupling chromatin architecture to metastasis, plus an m6A axis controlling its mRNA.\",\n      \"evidence\": \"LLPS/condensate assays with IDR deletion and S625/S628 phosphosite mutagenesis, CTCF Co-IP in condensates, chromatin-looping ChIP, in vivo metastasis; m6A-RIP/RIP and stability assays (METTL3/IGF2BP1, YTHDF2 loop); LLPS-dependent SLC3A2 activation in DLBCL\",\n      \"pmids\": [\"40185097\", \"39159608\", \"39987125\", \"40730912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for hypoxia-induced S625/S628 phosphorylation not identified\", \"Relationship between condensate formation and classical dimerization/cofactor binding unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular determinant that switches ZHX2 between transcriptional repression and co-activation across tissues remains undefined.\",\n      \"evidence\": \"No experiment in the corpus isolates the cofactor, modification, or DNA-context rule that toggles ZHX2 output mode\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of ZHX2 on DNA or with its partners\", \"No unified model reconciling repressor (liver) and activator (ccRCC/TNBC) functions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 6, 10, 14, 18]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 10, 20, 22, 24]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 6, 24]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 14, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 9, 11, 18]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 16, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 15, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ZHX3\", \"ZHX1\", \"VHL\", \"USP13\", \"NRMT1\", \"HIF1A\", \"RELA\", \"CTCF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}